At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
L. johnsonii N6.2 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Host Response to Lactobacillus Johnsonii
In Brief
A Phase 2 clinical trial evaluating L. johnsonii N6.2 and Placebo for Healthy. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine the effects of the probiotic, Lactobacillus johnsonii N6.2, on safety, gastrointestinal function, wellness, fecal bacteria and blood biomarkers in healthy individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsJuvenile Diabetes Research Foundation
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartAug 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedJan 28, 2015
Enrollment StartAug 1, 2015
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.4 years ago
Interventions
L. johnsonii N6.2biological
L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks
Placebobiological
Encapsulated starch placebo administered for 8 weeks